Overview

Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization

Status:
Completed
Trial end date:
2018-08-22
Target enrollment:
Participant gender:
Summary
The objectives of this study are to investigate the safety and effectiveness of EYLEA.
Details
Lead Sponsor:
Bayer
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Aflibercept